{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:49:39Z","timestamp":1776685779698,"version":"3.51.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018531","name":"Major Science and Technology Projects in Yunnan Province","doi-asserted-by":"publisher","award":["202402AA310016"],"award-info":[{"award-number":["202402AA310016"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018531","name":"Major Science and Technology Projects in Yunnan Province","doi-asserted-by":"publisher","award":["202202AG050008"],"award-info":[{"award-number":["202202AG050008"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Talent Project - Famous Doctor Project of Yunnan Province","award":["MY-2022-0029"],"award-info":[{"award-number":["MY-2022-0029"]}]},{"name":"Basic Research Program project of Yunnan Province","award":["202501AY070001-115"],"award-info":[{"award-number":["202501AY070001-115"]}]},{"name":"The open project of the Clinical Medical Center for Thoracic Diseases of the First People's Hospital of Yunnan Province","award":["2021LCZXXF-XB01"],"award-info":[{"award-number":["2021LCZXXF-XB01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32160157"],"award-info":[{"award-number":["32160157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160564"],"award-info":[{"award-number":["82160564"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Revitalization Talent Support Program","award":["CA24129L025A"],"award-info":[{"award-number":["CA24129L025A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02798-z","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:16:15Z","timestamp":1773310575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase \u03b1-subunit and RAS degradation"],"prefix":"10.1186","volume":"24","author":[{"given":"Guancong","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiameng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"9","key":"2798_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2798_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362\u201387.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2798_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"GP Kalemkerian","year":"2018","unstructured":"Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(9):911\u201319.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2798_CR4","doi-asserted-by":"publisher","first-page":"188967","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188967.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2798_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159.","journal-title":"Mol Cancer"},{"issue":"2","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1056\/NEJMe2206831","volume":"387","author":"DL Longo","year":"2022","unstructured":"Longo DL, Rosen N, Targeting Oncogenic RAS, Protein. N Engl J Med. 2022;387(2):184\u201386.","journal-title":"N Engl J Med"},{"issue":"4","key":"2798_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029\u201338.","journal-title":"Cancer Metastasis Rev"},{"key":"2798_CR8","doi-asserted-by":"crossref","unstructured":"Marchwicka A, Kaminska D, Monirialamdari M, Blazewska KM, Gendaszewska-Darmach E. Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization. Int J Mol Sci. 2022;23(10):5424.","DOI":"10.3390\/ijms23105424"},{"issue":"8","key":"2798_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. J Thorac Oncol. 2021;16(8):1321\u201332.","journal-title":"J Thorac Oncol"},{"issue":"6659","key":"2798_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.adg9652","volume":"381","author":"CJ Schulze","year":"2023","unstructured":"Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381(6659):794\u201399.","journal-title":"Science"},{"issue":"8013","key":"2798_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629(8013):919\u201326.","journal-title":"Nature"},{"issue":"8013","key":"2798_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629(8013):927\u201336.","journal-title":"Nature"},{"key":"2798_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.semcancer.2017.10.010","volume":"56","author":"SG Klochkov","year":"2019","unstructured":"Klochkov SG, Neganova ME, Yarla NS, Parvathaneni M, Sharma B, Tarasov VV, et al. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. Semin Cancer Biol. 2019;56:128\u201334.","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"2798_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.20.02903","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021;39(17):1856\u201364.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2798_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","volume":"130","author":"M Baranyi","year":"2024","unstructured":"Baranyi M, Molnar E, Hegedus L, Gabriel Z, Petenyi FG, Bordas F, et al. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. Br J Cancer. 2024;130(6):1059\u201372.","journal-title":"Br J Cancer"},{"key":"2798_CR16","doi-asserted-by":"crossref","unstructured":"Yu JJ, Zhang LJ, Peng J, Ward R, Hao PQ, Wang JW et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K\/AKT\/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2022;195:114864.","DOI":"10.1016\/j.bcp.2021.114864"},{"issue":"7","key":"2798_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","volume":"16","author":"DS Ettinger","year":"2018","unstructured":"Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807\u201321.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2798_CR18","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991.","journal-title":"Nat Commun"},{"issue":"2","key":"2798_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"key":"2798_CR20","doi-asserted-by":"publisher","first-page":"114864","DOI":"10.1016\/j.bcp.2021.114864","volume":"195","author":"J Yu","year":"2022","unstructured":"Yu J, Zhang L, Peng J, Ward R, Hao P, Wang J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K\/AKT\/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2022;195:114864.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"2798_CR21","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2024.02.042","volume":"187","author":"RA Weinberg","year":"2024","unstructured":"Weinberg RA. It took a long, long time: Ras and the race to cure cancer. Cell. 2024;187(7):1574\u201377.","journal-title":"Cell"},{"issue":"10","key":"2798_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/s41589-024-01691-5","volume":"20","author":"JML Ostrem","year":"2024","unstructured":"Ostrem JML, Peters U, Shokat KM. Direct RAS inhibitors turn 10. Nat Chem Biol. 2024;20(10):1238\u201341.","journal-title":"Nat Chem Biol"},{"issue":"10","key":"2798_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"2798_CR24","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","volume":"89","author":"D Uprety","year":"2020","unstructured":"Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020;89:102070.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2798_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/10600280231197459","volume":"58","author":"N Mausey","year":"2024","unstructured":"Mausey N, Halford Z. Targeted Therapies for Previously Undruggable KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib. Ann Pharmacother. 2024;58(6):622\u201335.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"2798_CR26","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28(10):2171\u201382.","journal-title":"Nat Med"},{"issue":"7968","key":"2798_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, Bottcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619(7968):160\u201366.","journal-title":"Nature"},{"issue":"6","key":"2798_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024;14(6):994\u20131017.","journal-title":"Cancer Discov"},{"issue":"1","key":"2798_CR29","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"MJ Nokin","year":"2024","unstructured":"Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024;15(1):7554.","journal-title":"Nat Commun"},{"issue":"6","key":"2798_CR30","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","volume":"68","author":"J Cregg","year":"2025","unstructured":"Cregg J, Pota K, Tomlinson ACA, Yano J, Marquez A, Liu Y, et al. Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers. J Med Chem. 2025;68(6):6041\u201363.","journal-title":"J Med Chem"},{"issue":"25","key":"2798_CR31","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021;384(25):2382\u201393.","journal-title":"N Engl J Med"},{"issue":"8","key":"2798_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021;11(8):1913\u201322.","journal-title":"Cancer Discov"},{"issue":"7790","key":"2798_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421\u201325.","journal-title":"Nature"},{"issue":"7","key":"2798_CR34","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, de la Fece F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition. Clin Cancer Res. 2020;26(7):1633\u201343.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2798_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1039\/C7MD00030H","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. Medchemcomm. 2017;8(5):841\u201354.","journal-title":"Medchemcomm"},{"issue":"1","key":"2798_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/mol.110.063586","volume":"78","author":"CK Kim","year":"2010","unstructured":"Kim CK, Choi YK, Lee H, Ha KS, Won MH, Kwon YG, et al. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase\/Akt signal pathways. Mol Pharmacol. 2010;78(1):142\u201350.","journal-title":"Mol Pharmacol"},{"issue":"22","key":"2798_CR37","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1021\/bi049723b","volume":"43","author":"TS Reid","year":"2004","unstructured":"Reid TS, Beese LS. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry. 2004;43(22):6877\u201384.","journal-title":"Biochemistry"},{"issue":"10","key":"2798_CR38","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-06-4044","volume":"67","author":"Y Qiu","year":"2007","unstructured":"Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, et al. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 2007;67(10):4973\u201380.","journal-title":"Cancer Res"},{"issue":"3","key":"2798_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/cvr\/cvw258","volume":"113","author":"L Duluc","year":"2017","unstructured":"Duluc L, Ahmetaj-Shala B, Mitchell J, Abdul-Salam VB, Mahomed AS, Aldabbous L, et al. Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovasc Res. 2017;113(3):276\u201387.","journal-title":"Cardiovasc Res"},{"key":"2798_CR40","doi-asserted-by":"publisher","first-page":"106462","DOI":"10.1016\/j.intimp.2020.106462","volume":"83","author":"J Guo","year":"2020","unstructured":"Guo J, Shirozu K, Akahoshi T, Mizuta Y, Murata M, Yamaura K. The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A. Int Immunopharmacol. 2020;83:106462.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2798_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/SHK.0000000000000239","volume":"42","author":"K Shirozu","year":"2014","unstructured":"Shirozu K, Hirai S, Tanaka T, Hisaka S, Kaneki M, Ichinose F. Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine\/lipopolysaccharide-induced acute liver failure. Shock. 2014;42(6):570\u201377.","journal-title":"Shock"},{"issue":"1","key":"2798_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/BST20110609","volume":"40","author":"E Aksamitiene","year":"2012","unstructured":"Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras\/MAPK and survival PI3K\/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(1):139\u201346.","journal-title":"Biochem Soc Trans"},{"key":"2798_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","volume":"459","author":"Z Cao","year":"2019","unstructured":"Cao Z, Liao Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: The way forward? Cancer Lett. 2019;459:30\u201340.","journal-title":"Cancer Lett"},{"issue":"10","key":"2798_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1541-7786.MCR-15-0506","volume":"14","author":"JY Kim","year":"2016","unstructured":"Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, et al. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res. 2016;14(10):1019\u201329.","journal-title":"Mol Cancer Res"},{"issue":"41","key":"2798_CR45","doi-asserted-by":"publisher","first-page":"eade3816","DOI":"10.1126\/sciadv.ade3816","volume":"9","author":"A Mohanty","year":"2023","unstructured":"Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, et al. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer. Sci Adv. 2023;9(41):eade3816.","journal-title":"Sci Adv"},{"issue":"1","key":"2798_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","volume":"23","author":"WJ McDaid","year":"2024","unstructured":"McDaid WJ, Wilson L, Adderley H, Martinez-Lopez A, Baker MJ, Searle J, et al. The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS(G12D)-driven non-small cell lung cancer. Mol Cancer. 2024;23(1):253.","journal-title":"Mol Cancer"},{"issue":"2","key":"2798_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2025;11(2):91\u2013116.","journal-title":"Trends Cancer"},{"issue":"2","key":"2798_CR48","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","volume":"25","author":"S Misale","year":"2019","unstructured":"Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, et al. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clin Cancer Res. 2019;25(2):796\u2013807.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2798_CR49","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.1038\/s41467-024-50063-z","volume":"15","author":"H Kitai","year":"2024","unstructured":"Kitai H, Choi PH, Yang YC, Boyer JA, Whaley A, Pancholi P, et al. Combined inhibition of KRAS(G12C) and mTORC1 kinase is synergistic in non-small cell lung cancer. Nat Commun. 2024;15(1):6076.","journal-title":"Nat Commun"},{"issue":"7","key":"2798_CR50","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-19-3053","volume":"26","author":"JFR Robertson","year":"2020","unstructured":"Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, et al. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER(+) Invasive Breast Cancer (STAKT). Clin Cancer Res. 2020;26(7):1574\u201385.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2798_CR51","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nchembio.183","volume":"5","author":"T Okuzumi","year":"2009","unstructured":"Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol. 2009;5(7):484\u201393.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2798_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17(1):53.","journal-title":"Mol Cancer"},{"issue":"9","key":"2798_CR53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"12","key":"2798_CR54","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","volume":"75","author":"CA Eberlein","year":"2015","unstructured":"Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res. 2015;75(12):2489\u2013500.","journal-title":"Cancer Res"},{"issue":"10","key":"2798_CR55","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","volume":"9","author":"H Linardou","year":"2008","unstructured":"Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962\u201372.","journal-title":"Lancet Oncol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02798-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02798-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02798-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:03:49Z","timestamp":1776683029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02798-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02798-z","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were conducted in accordance with the ARRIVE guidelines and were approved by the Laboratory Animal Welfare Ethics Committee of Yunnan University (YNU20241147). Additionally, the patient-derived organoids assays complied with the Declaration of Helsinki and were approved by the Ethics Committee of Kunming University of Science and Technology (KMUST-MEC-2024-070).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}